GH Guardant Health, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
16:16
Sep 30
Sep 30
Monetary Matters
AI drug discovery tools beat picking winners
AI can now model cells, organs, tissue, and disease biology at scale and screen molecules computationally, shifting drug discovery from expensive trial-and-error toward data-driven target selection. Rather than picking which drug company wins, Ben prefers the tools that measure, test, collect, create, and sequence biological data, citing a basket including Danaher, Thermo Fisher, Schrödinger, Illumina, Guardant Health, and Twist Bioscience.
GH
Guardant Health, Inc.
Long
1ST
—
—
08:30
Jul 19
Jul 19
815 Money Talk
Buy Guardant Health and Natera on biotech rotation.
Retail investors are rotating out of crowded tech positions into biotech and healthcare. Guardant Health (liquid biopsy, early cancer detection) and Natera (genetic testing, recurrence monitoring) are leading liquid-biopsy companies that rank high among retail purchases. This rotation into defensive biotech leaders gives them added demand and supports a positive outlook.
GH
Guardant Health, Inc.
Long
1ST
—
—
12:00
Apr 21
Apr 21
ILTB Podcast
Cancer screening companies are growing rapidly.
Companies like Exact Sciences and Guardant Health are advancing colorectal cancer screening with stool-based and blood tests, respectively, making screening more convenient and increasing adoption. Blood tests are inflecting and multi-cancer early detection tests are emerging, which could lead to earlier cancer detection and better outcomes.
GH
Guardant Health, Inc.
Long
1ST
—
—
About GH Investor Commentary
Across the available history and selected sources, Buzzberg tracks GH (Guardant Health, Inc.) across 9 sources: 3 bullish vs 0 bearish calls from 9 authors. Historical directional balance: 15% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 20 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Ben Pouladian, Choi Chang-gyu, Alex Karnal.